Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.

[1]  K. Kario,et al.  Blood pressure variability in elderly patients , 2000, The Lancet.

[2]  P. Deedwania,et al.  Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). , 2002, American heart journal.

[3]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[4]  D. Waters,et al.  Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? , 2004, The American journal of cardiology.

[5]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[6]  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[7]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[8]  P. Thompson,et al.  Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance , 2008, The Annals of pharmacotherapy.

[9]  E. O’Brien,et al.  Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension , 2010, The Lancet.

[10]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[11]  G. Barnas,et al.  Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. , 2011, Journal of clinical lipidology.

[12]  A. Wierzbicki,et al.  Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study , 2012, Current medical research and opinion.

[13]  Cholesterol Treatment Trialists' Collaborato.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012 .

[14]  R. Giugliano,et al.  Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study , 2012, The Lancet.

[15]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[16]  F. Parvez,et al.  A prospective study of variability in systolic blood pressure and mortality in a rural Bangladeshi population cohort. , 2013, Preventive medicine.

[17]  R. Hegele,et al.  Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. , 2013, The Canadian journal of cardiology.

[18]  N. Kressin,et al.  A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol. , 2013, The American journal of cardiology.

[19]  Shah Ebrahim,et al.  Statins for the primary prevention of cardiovascular disease (Review) , 2011 .

[20]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.